Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.

Chu NI, Chan RL, Hama KM, Chaplin MD

Drug metabolism and disposition: the biological fate of chemicals1 Sept 1985Cited by 13 (Europe PMC)

PMID2865103DOI10.1016/s0090-9556(25)08250-9PepBankPUB-02865103

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In male rats, radiolabeled nafarelin distributed rapidly, with highest radioactivity in kidneys, liver and intestines.
In plain wordsIn rats, radiolabeled nafarelin distributed rapidly, with highest radioactivity in kidneys, liver and intestines.
Peptide
Nafarelin
Outcome
Not applicableTissue distribution
Study
ratn: not reported in source
male rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 micrograms · intravenousAs given in this study (rat).
Source sentences
Summary
Distribution of a single 100-micrograms dose [14C]nafarelin acetate into tissues in male rats was rapid and of the 13 tissues assayed, highest concentrations of radioactivity were observed in the kidneys, liver, and intestines.
1 context sentence(design, population, supporting numbers)
Summary · context
We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species.
Report a problemFND-0286510301
02AnimalAnimal study (in vivo)Pharmacokinetics
In rhesus monkeys, nafarelin-associated radioactivity had a urine to feces ratio of 4:1.
In plain wordsIn rhesus monkeys, nafarelin-associated radioactivity had a urine to feces ratio of 4:1.
Peptide
Nafarelin
Outcome
Not applicableUrine to feces radioactivity ratio
Study
rhesus monkeyn: not reported in source
rhesus monkeys
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intravenousAs given in this study (rhesus monkey).
Source sentences
Summary
The urine to feces ratio of nafarelin-associated 14C was 4:1 in rhesus monkeys and 1:3 in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species.
Report a problemFND-0286510302
03AnimalAnimal study (in vivo)Pharmacokinetics
In rats, nafarelin-associated radioactivity had a urine to feces ratio of 1:3.
In plain wordsIn rats, nafarelin-associated radioactivity had a urine to feces ratio of 1:3.
Peptide
Nafarelin
Outcome
Not applicableUrine to feces radioactivity ratio
Study
ratn: not reported in source
rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
The urine to feces ratio of nafarelin-associated 14C was 4:1 in rhesus monkeys and 1:3 in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species.
Report a problemFND-0286510303
04AnimalAnimal study (in vivo)Pharmacokinetics
In female rhesus monkeys, nafarelin had a terminal half-life of 120 min versus 33 min for LHRH.
In plain wordsIn rhesus monkeys, nafarelin had a longer terminal half-life than LHRH.
Peptide
Nafarelin
Outcome
IncreaseTerminal plasma half-life
Study
rhesus monkeyn: not reported in source
female rhesus monkeys
Comparator
LHRH
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
6.5 nmol/kg · intravenousAs given in this study (rhesus monkey).
Source sentences
Summary
Nafarelin acetate and LHRH given iv to female rhesus monkeys in approximately equimolar doses (6.5 nmol/kg) had terminal plasma t1/2 values of 120 min and 33 min, and systemic clearance values of 2.7 ml/min/kg and 31.4 ml/min/kg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species.
Report a problemFND-0286510304
05AnimalAnimal study (in vivo)Pharmacokinetics
In female rhesus monkeys, nafarelin clearance was 2.7 ml/min/kg versus 31.4 ml/min/kg for LHRH.
In plain wordsIn rhesus monkeys, nafarelin clearance was lower than LHRH clearance.
Peptide
Nafarelin
Outcome
DecreaseSystemic clearance
Study
rhesus monkeyn: not reported in source
female rhesus monkeys
Comparator
LHRH
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
6.5 nmol/kg · intravenousAs given in this study (rhesus monkey).
Source sentences
Summary
Nafarelin acetate and LHRH given iv to female rhesus monkeys in approximately equimolar doses (6.5 nmol/kg) had terminal plasma t1/2 values of 120 min and 33 min, and systemic clearance values of 2.7 ml/min/kg and 31.4 ml/min/kg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species.
Report a problemFND-0286510305
06AnimalAnimal study (in vivo)Pharmacokinetics
In female rats, nafarelin half-life was 33.6 min versus 6.7 min for LHRH.
In plain wordsIn rats, nafarelin had a longer plasma half-life than LHRH.
Peptide
Nafarelin
Outcome
IncreasePlasma half-life
Study
ratn: not reported in source
female rats
Comparator
LHRH
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
In female rats, the plasma t1/2 was 33.6 min for nafarelin acetate and 6.7 min for LHRH, and the systemic clearance values for nafarelin acetate and LHRH were 12.0 ml/min/kg and 57.6 ml/min/kg, respectively, after approximately equimolar doses.
1 context sentence(design, population, supporting numbers)
Summary · context
We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species.
Report a problemFND-0286510306
07AnimalAnimal study (in vivo)Pharmacokinetics
In female rats, nafarelin clearance was 12.0 ml/min/kg versus 57.6 ml/min/kg for LHRH.
In plain wordsIn rats, nafarelin clearance was lower than LHRH clearance.
Peptide
Nafarelin
Outcome
DecreaseSystemic clearance
Study
ratn: not reported in source
female rats
Comparator
LHRH
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
In female rats, the plasma t1/2 was 33.6 min for nafarelin acetate and 6.7 min for LHRH, and the systemic clearance values for nafarelin acetate and LHRH were 12.0 ml/min/kg and 57.6 ml/min/kg, respectively, after approximately equimolar doses.
1 context sentence(design, population, supporting numbers)
Summary · context
We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species.
Report a problemFND-0286510307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.